Sell2Wales.gov.wales uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies.

Accept cookies Cookie Settings

View Notice

The buyer is not using this website to administer the notice. To record your interest or obtain additional information or documents please find instructions within the Full Notice Text. (NOTE: Contract Award Notices and Prior Information Notices do not normally require a response)

Add notice to my Sell2Wales Interest List

Notice Details

Title: (NU1433-10) RAR-M Therapeutics Ltd: The Provision of Business Consultancy to Assist Commercialisation of University Research
Published by: Newcastle University
Publication Date: 22/05/2020
Deadline Date:
Deadline Time:
Notice Type: Contract Award Notice
Has Documents: No
Has ESPD: No
Abstract:

Newcastle, Durham, Sunderland and Northumbria universities, in common with universities throughout the UK, have advanced relevant systems and procedures and also dedicate significant public resource to both research and commercialisation of that research. A key route to commercialisation is the creation of a new business (a spin-out company) wherein the intellectual property (IPR) developed exclusively licensed to a university start-up company in exchange for (founders) shares in that company.

The universities ill engage suitably qualified and experienced executives through the DPS as and when required over the DPS period. The specific requirements will be detailed in each further competition.

The initial brief of the executive for which he/she will be paid, dependent upon the scope of the specific project engagement sought, either a payment or a combination of a payment and a share/stock option will typically be to:

(a) produce a viable business plan;

(b) obtain university approval for the venture;

(c) act for the company in the spin-out legal process and address all the company formation matters;

(d) provide to the appropriate university all matters necessary for ESIF, ERDF and Research England reporting requirements;

(e) secure (venture capital and/or other) funding in accordance with the business plan.

Contract award notice

Results of the procurement procedure

Directive 2014/24/EU - Public Sector Directive

Directive 2014/24/EU

Section I: Contracting entity

I.1) Name and addresses

Newcastle University

Procurement Services, Kingsgate

Newcastle

NE1 7RU

UK

Contact person: Mrs Natalie Morton

Telephone: +44 1912086396

E-mail: natalie.morton@ncl.ac.uk

NUTS: UKC

Internet address(es)

Main address: www.ncl.ac.uk

Address of the buyer profile: www.ncl.ac.uk

I.1) Name and addresses

Durham University

The Palatine Centre, Stockton Road

Durham

UK

E-mail: Edwin.e.milligan@durham.ac.uk

NUTS: UKC

Internet address(es)

Main address: https://www.durham.ac.uk

I.1) Name and addresses

Northumbria University Newcastle

Newcastle

NE1 1XE

UK

E-mail: Hugh.Rhodes@northumbria.ac.uk

NUTS: UK

Internet address(es)

Main address: https://northumbria.ac.uk

I.1) Name and addresses

University of Sunderland

Sunderland

UK

E-mail: Cheryl.Holmstrom@sunderland.ac.uk

NUTS: UK

Internet address(es)

Main address: https://Sunderland.ac.uk

I.2) Joint procurement

The contract involves joint procurement

The contract is awarded by a central purchasing body

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Education

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

(NU1433-10) RAR-M Therapeutics Ltd: The Provision of Business Consultancy to Assist Commercialisation of University Research

Reference number: DN473477

II.1.2) Main CPV code

79400000

 

II.1.3) Type of contract

Services

II.1.4) Short description

Amyotrophic lateral sclerosis (ALS) — as with most other neurodegenerative diseases, including Alzheimer's and Parkinson’s — is a major medical challenge and is having an ever-increasing impact upon the lives of patients, carers and indeed of society as a whole. Scientists at Durham (Chemistry Department) and Aberdeen Universities have recently designed, synthesised and identified a lead drug candidate with the potential for establishing a new treatment approach for ALS and with a longer-term potential of being effective for other neurodegenerative diseases.

The technology is now being patented and we are ready to develop a commercial vehicle to drive the drug development programme forwards and raise the necessary investment required for the next stages. The need for an experienced Business Executive/CEO, who has already delivered drugs to the market in the neurodegenerative area, is essential to support the commercial team and especially the CEO directly. Although two of the team have commercial (spinout) experience (e.g. as CTO of LightOx who are successfully raising second phase major investment currently for LightOx), the successful launch of market leading drugs and the raising of the finance to make that happen is needed to successfully take the company forward.

In the longer term (such as Phase III raise of ca. GBP 100+ million), such an executive might well be appointed as CEO, but in these early development stages, advise and business support is required.

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement

Value excluding VAT: 30 000.00 GBP

II.2) Description

II.2.3) Place of performance

NUTS code:

UKC

II.2.4) Description of the procurement

Newcastle, Durham, Sunderland and Northumbria universities, in common with universities throughout the UK, have advanced relevant systems and procedures and also dedicate significant public resource to both research and commercialisation of that research. A key route to commercialisation is the creation of a new business (a spin-out company) wherein the intellectual property (IPR) developed exclusively licensed to a university start-up company in exchange for (founders) shares in that company.

The universities ill engage suitably qualified and experienced executives through the DPS as and when required over the DPS period. The specific requirements will be detailed in each further competition.

The initial brief of the executive for which he/she will be paid, dependent upon the scope of the specific project engagement sought, either a payment or a combination of a payment and a share/stock option will typically be to:

(a) produce a viable business plan;

(b) obtain university approval for the venture;

(c) act for the company in the spin-out legal process and address all the company formation matters;

(d) provide to the appropriate university all matters necessary for ESIF, ERDF and Research England reporting requirements;

(e) secure (venture capital and/or other) funding in accordance with the business plan.

II.2.5) Award criteria

Quality criterion: Quality / Weighting: 70

Cost criterion: Price / Weighting: 30

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: Yes

II.2.14) Additional information

The Northern Accelerator brand is supported by Research England which is responsible for funding, engaging with and understanding English higher education institutions (HEIs).The Connecting Capability Fund (CCF) supports university collaboration in research commercialisation.

The Northern Accelerator programme is also supported by a European Regional Development Fund (ERDF) project that supports the commercialisation of university research, also delivered under the Northern Accelerator brand.

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Restricted procedure

IV.1.3) Information about a framework agreement or a dynamic purchasing system

A dynamic purchasing system was set up

IV.1.8) Information about Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.1) Previous publication concerning this procedure

Notice number in the OJ S:

2019/S 009-016574

Section V: Award of contract

Contract No: NU1433-10

A contract/lot is awarded: Yes

V.2 Award of contract

V.2.1) Date of conclusion of the contract

22/04/2020

V.2.2) Information about tenders

Number of tenders received: 2

Number of tenders received from SMEs: 2

Number of tenders received from tenderers from other EU Member States: 0

Number of tenders received from tenderers from non-EU Member States: 0

Number of tenders received by electronic means: 2

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

DyoDelta Biosciences Ltd

Greater London

UK

NUTS: UKC

The contractor is an SME: Yes

V.2.4) Information on value of the contract/lot (excluding VAT)

Total value of the contract/lot: 30 000.00 GBP

V.2.5) Information about subcontracting

Section VI: Complementary information

VI.4) Procedures for review

VI.4.1) Review body

Newcastle University

Tyne and Wear

NE1 7RU

UK

VI.4.2) Body responsible for mediation procedures

Newcastle University

Tyne and Wear

UK

VI.4.3) Review procedure

Precise information on deadline(s) for review procedures:

Newcastle University has incorporated a minimum 10 calendar day standstill period at the point information on the award of the contract was communicated to tenderers. This period allowed unsuccessful tenderers to see further debriefing before the contract was entered into. Such additional information would be requested from the address referred to in Part 1.1 above. If an appeal regarding the award contract has not been successfully resolved, the Public contracts Regulations 2015 provide for aggrieved parties who have been harmed or are at risk of harm by breach of the rules to take action in the high court (England, Wales and Northern Ireland). Any such action must be brought promptly. Where a contract has not been entered into the court may order the setting aside of the award decision in order for the authority to amend any document and may award damages. If the contract has been entered into court may only award damages.

VI.4.4) Service from which information about the review procedure may be obtained

Newcastle University

Tyne and Wear

UK

VI.5) Date of dispatch of this notice

19/05/2020


Information added to the notice since publication.

Additional information added to the notice since it's publication.
No further information has been uploaded.
Main Contact: natalie.morton@ncl.ac.uk
Admin Contact: N/a
Technical Contact: N/a
Other Contact: N/a

Commodity Categories

Commodity Categories
IDTitleParent Category
79400000Business and management consultancy and related servicesBusiness services: law, marketing, consulting, recruitment, printing and security

Delivery Locations

Delivery Locations
IDDescription
100UK - All

Alert Region Restrictions

The buyer has restricted the alert for this notice to suppliers based in the following regions.

Alert Region Restrictions
There are no alert restrictions for this notice.

Copyright © Sell2Wales